US Federal House Bill HJR168

US Federal 2025-2026 Regular Session

• Introduced: 4/30/26
• Refer: 4/30/26

Caption

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Bulletin 2022-01: Medical Debt Collection and Consumer Reporting Requirements in Connection with the No Surprises Act".

Impact

The implications of HJR168 on state laws and consumer protection are significant. By disapproving the CFPB’s rule withdrawal, the bill aims to restore protections that prevent the aggressive collection of medical debt and clarify the expectations around consumer reporting in these circumstances. Advocates argue that this could minimize confusion and protect consumers from sudden medical costs that fall outside of their control, which is crucial in maintaining financial stability for households. Conversely, there are concerns about the regulatory burden this reinstatement may place on healthcare providers and the potential impacts on medical billing practices moving forward.

Summary

HJR168 is a joint resolution that seeks to disapprove a rule submitted by the Bureau of Consumer Financial Protection (CFPB) regarding medical debt collection and its reporting requirements under the No Surprises Act. Specifically, the resolution targets the withdrawal of Bulletin 2022–01, which outlines guidelines for how medical debt is to be collected and reported in cases involving unexpected medical bills. By providing for the disapproval of this rule, HJR168 attempts to reinstate the previous regulations aimed at ensuring consumer protection in financial transactions related to medical care.

Contention

The resolution has sparked a contentious debate among lawmakers and stakeholders in the healthcare and financial sectors. Supporters of HJR168, primarily from consumer advocacy groups, argue for the necessity of maintaining strict consumer protections against medical debt, which they acknowledge can result in significant stress and financial harm. On the other hand, opponents, including some healthcare providers and financial entities, raise concerns about the impact on operational practices, arguing that the reinstated regulations may lead to inefficiencies and hinder the ability of healthcare providers to collect debts that are legitimately owed. Additionally, discussions have revolved around the balance between consumer protection and the operational realities faced by medical institutions in billing and collections.

Final_notes

Overall, HJR168 emphasizes the ongoing tension between regulatory measures and the interests of individual consumers versus those of the healthcare and financial sectors. The outcome of this resolution will reflect broader trends in how medical debt is handled in relation to consumer rights and protections, as well as the regulatory landscape governing financial interactions in healthcare.